Inovio Pharmaceuticals, Inc. (INO)’s director Simon Benito Sold 3,750 Shares; National American University Holdings (NAUH) Sentiment Is 0

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Logo

Sentiment for National American University Holdings Inc (NAUH)

National American University Holdings Inc (NAUH) investors sentiment decreased to 0 in Q4 2017. It’s down -0.75, from 0.75 in 2017Q3. The ratio fall, as 0 investment managers increased and started new positions, while 8 sold and decreased their stakes in National American University Holdings Inc. The investment managers in our database now own: 3.02 million shares, down from 3.20 million shares in 2017Q3. Also, the number of investment managers holding National American University Holdings Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 6 Increased: 0 New Position: 0.

National American University Holdings, Inc. owns and operates National American University that provides professional and technical postsecondary education primarily for working adults and other non-traditional students in the United States. The company has market cap of $25.30 million. It operates in two divisions, NAU and Other. It currently has negative earnings. The firm offers diploma, associate, baccalaureate, masterÂ’s, and doctoral degree programs in business-related disciplines, such as accounting, management, business administration, and information technology; healthcare-related disciplines, including occupational therapy, medical assisting, nursing, surgical technology, and healthcare information and management; legal-related disciplines comprising paralegal, criminal justice, and professional legal studies; and higher education.

The stock decreased 5.45% or $0.06 during the last trading session, reaching $1.04. About 2,447 shares traded. National American University Holdings, Inc. (NAUH) has declined 50.20% since April 14, 2017 and is downtrending. It has underperformed by 61.75% the S&P500.

Blackrock Inc. holds 0% of its portfolio in National American University Holdings, Inc. for 36,714 shares. Bridgeway Capital Management Inc owns 280,000 shares or 0% of their US portfolio. Moreover, Brown Advisory Inc has 0% invested in the company for 44,900 shares. The Maryland-based Df Dent & Co Inc has invested 0% in the stock. Dimensional Fund Advisors Lp, a Texas-based fund reported 21,922 shares.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $458.95 million. The Company’s SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals has $31 highest and $9 lowest target. $14.67’s average target is 189.92% above currents $5.06 stock price. Inovio Pharmaceuticals had 41 analyst reports since August 10, 2015 according to SRatingsIntel. H.C. Wainwright maintained the shares of INO in report on Friday, January 12 with “Buy” rating. Brean Capital maintained the shares of INO in report on Monday, March 14 with “Buy” rating. The rating was maintained by H.C. Wainwright on Wednesday, January 3 with “Buy”. H.C. Wainwright maintained the shares of INO in report on Thursday, March 15 with “Buy” rating. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) earned “Hold” rating by Maxim Group on Tuesday, August 9. As per Tuesday, November 28, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, March 21. The firm earned “Buy” rating on Monday, June 26 by Stifel Nicolaus. Piper Jaffray maintained the shares of INO in report on Monday, August 10 with “Overweight” rating. The firm earned “Buy” rating on Friday, October 6 by H.C. Wainwright.

Investors sentiment is 2 in Q4 2017. Its the same as in 2017Q3. It is the same, as 0 investors sold Inovio Pharmaceuticals, Inc. shares while 1 reduced holdings. only 1 funds opened positions while 1 raised stakes. 44,744 shares or 7.51% more from 41,620 shares in 2017Q3 were reported. First Dallas Secs holds 0.07% in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) or 4,400 shares. Pnc Gru has invested 0% in Inovio Pharmaceuticals, Inc. (NASDAQ:INO). Shapiro Mngmt Ltd Liability Corp invested in 10,000 shares. Neville Rodie & Shaw Inc has invested 0.03% in Inovio Pharmaceuticals, Inc. (NASDAQ:INO). Parametric Portfolio Assocs Lc stated it has 0% of its portfolio in Inovio Pharmaceuticals, Inc. (NASDAQ:INO).

Simon Benito, an insider and also director of the well-known company Inovio Pharmaceuticals Inc made transaction. He made a sale of 3,750 shares of the company with the insider transaction having a value near $19,619 US Dollars – based on a market price of $5.2 per each share. And, It’s sure Simon’s sell isn’t going to stay undiscovered as he today is having ownership of 27,798 shares – ( 0.03% of Inovio Pharmaceuticals Inc’s Market Cap ).

The stock decreased 1.94% or $0.1 during the last trading session, reaching $5.06. About 790,433 shares traded. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has declined 24.44% since April 14, 2017 and is downtrending. It has underperformed by 35.99% the S&P500.

National American University Holdings, Inc. (NASDAQ:NAUH) Institutional Positions Chart